Authors
Latest:
Effective Palliative Care: What Is Involved?This article reviews the ways in which palliative care and oncology teams can collaborate to provide high-quality care to patients and their families; it also provides practical tips for oncologists who wish to initiate primary palliative care for their patients.
Latest:
Effective Palliative Care: What Is Involved?This article reviews the ways in which palliative care and oncology teams can collaborate to provide high-quality care to patients and their families; it also provides practical tips for oncologists who wish to initiate primary palliative care for their patients.
Latest:
Utility of the 21-Gene Recurrence Score in Node-Positive Breast CancerABSTRACT The 21-gene Recurrence Score (RS) assay has been validated as both a prognostic and predictive tool in node-negative (pN0), estrogen receptor–positive (ER+), HER2-negative (HER2–) breast cancer. A large body of evidence supports the clinical utility of the RS in the node positive (pN+) population as well. Retrospective analyses of archived tissue from multiple clinical trials have found the RS to be prognostic in both endocrine therapy (ET)-treated and chemotherapy-treated patients with pN+ disease. Distribution of RS results in pN+ patients have also been consistent with those of pN0 populations. Data from the SWOG 8814 trial and large population-based registries further support the prognostic and potential predictive value of the RS. Specifically, patients with 1 to 3 positive nodes and RS less than 18 derived negligible benefit from adjuvant chemotherapy in these studies. In the prospective West German Study Group PlanB and ADAPT trials, pN+ patients with RS less than 11 and RS ≤25, respectively, who were treated with ET alone experienced excellent outcomes. Finally, 5-year results of the RxPONDER clinical trial randomizing patients with 1 to 3 positive nodes and RS ≤25 to ET alone vs ET plus chemotherapy confirmed an absence of chemotherapy benefit in postmenopausal patients. Clinical practice guidelines support use of the RS in the pN+, ER+/HER2– population, and many institutions have adopted the RS to guide clinical decision-making, resulting in a net reduction of adjuvant chemotherapy use. This review highlights the existing data supporting the prognostic and predictive ability of the RS in pN+ disease, current practice patterns related to RS use in this population, and emerging applications.
Latest:
POINT: LHRH Agonists vs Ovarian Ablation for Suppression of Ovarian Function in Premenopausal Breast Cancer PatientsReversible ovarian function suppression using LHRH agonists is the preferred first treatment for most premenopausal breast cancer patients.
Latest:
Secondary Prevention Strategies for Nonmelanoma Skin CancerIn this article, we review the published literature and evaluate secondary prevention strategies for nonmelanoma skin cancer. We also explore investigational therapies proposed for chemoprevention of nonmelanoma skin cancers.
Latest:
Secondary Prevention Strategies for Nonmelanoma Skin CancerIn this article, we review the published literature and evaluate secondary prevention strategies for nonmelanoma skin cancer. We also explore investigational therapies proposed for chemoprevention of nonmelanoma skin cancers.
Latest:
Immune Checkpoint Inhibitor Therapy in Patients With Autoimmune DiseaseIn this article, we detail the experience with immune checkpoint inhibitors in patients with autoimmune disease.
Latest:
Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid MalignanciesIn this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases.
Latest:
Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid MalignanciesIn this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases.
Latest:
Implications of Mutation Profiling in Myeloid Malignancies-PART 2: Myeloproliferative Neoplasms and Other Myeloid MalignanciesIn this second part of our two-part review, we discuss the use of mutation profiling in the diagnosis, prognosis, and treatment of patients with myeloproliferative neoplasms and other myeloid diseases.
Latest:
Clinical Pearls for Community Oncologists Treating MyelofibrosisThe panel closes their discussion on myelofibrosis treatment updates by sharing clinical pearls for community oncologists.
Latest:
Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung CancerIn this review, we discuss recent clinical investigations that highlight the effects of novel compounds targeting EGFR, ALK, and other receptor oncogenes, as well as the promise of immunotherapy in lung cancer CNS disease.
Latest:
Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung CancerIn this review, we discuss recent clinical investigations that highlight the effects of novel compounds targeting EGFR, ALK, and other receptor oncogenes, as well as the promise of immunotherapy in lung cancer CNS disease.
Latest:
Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung CancerIn this review, we discuss recent clinical investigations that highlight the effects of novel compounds targeting EGFR, ALK, and other receptor oncogenes, as well as the promise of immunotherapy in lung cancer CNS disease.
Latest:
Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung CancerIn this review, we discuss recent clinical investigations that highlight the effects of novel compounds targeting EGFR, ALK, and other receptor oncogenes, as well as the promise of immunotherapy in lung cancer CNS disease.
Latest:
Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung CancerIn this review, we discuss recent clinical investigations that highlight the effects of novel compounds targeting EGFR, ALK, and other receptor oncogenes, as well as the promise of immunotherapy in lung cancer CNS disease.
Latest:
Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung CancerIn this review, we discuss recent clinical investigations that highlight the effects of novel compounds targeting EGFR, ALK, and other receptor oncogenes, as well as the promise of immunotherapy in lung cancer CNS disease.
Latest:
Uncovering Epigenetic Targets in CancerDr. Stephen Baylin discusses his 2018 AACR meeting presentation on SU2C research into using epigenetic therapy to boost immune checkpoint therapy.
Latest:
Systemic Treatment Options for Brain Metastases from Non–Small-Cell Lung CancerIn this review, we discuss recent clinical investigations that highlight the effects of novel compounds targeting EGFR, ALK, and other receptor oncogenes, as well as the promise of immunotherapy in lung cancer CNS disease.
Latest:
Non-Clear Cell RCC: Key Learnings and Future Research DirectionsThe panel discusses key learnings from recent studies in non-clear cell RCC subtypes and the need to better understand disease biology to develop optimized, histology-specific therapies rather than extrapolating clear cell treatment approaches.
Latest:
OncoMasTR Assay May Help Some Breast Cancer Patients Avoid ChemoIn this video, Dr. Arman Rahman explains how the OncoMasTR protein assay may help women with breast cancer avoid unnecessary chemotherapy.
Latest:
Inhibit CXCR4 to Treat CRC and Pancreatic CancerIn this video, Dr. Douglas Fearon outlines ways that inhibiting CXCR4 may provoke an immune response to treat pancreatic and colorectal cancer.
Latest:
The 411 on TCGA: Share ‘Omics’ Data for Precision OncologyIn this video, Dr. Jean Zenklusen describes an NCI tool that enables researchers, clinicians, and patients to access an array of cancer-related data.
Latest:
Oncology Peer Review On-The-Go: Debra Patt, MD, PhD, MBA, on Telehealth in Cancer CareCancerNetwork® spoke with Debra Patt, MD, PhD, MBA, about the role of telehealth in caring for patients with cancer during the COVID-19 pandemic and beyond.
Latest:
Forecasting PARP Inhibitor Resistance in Breast Cancer PatientsIn this video, Dr. Elizabeth Swisher reviews the use of PARP inhibitors in breast cancer, and the importance of understanding how resistance to these agents develops.
Latest:
Xenograft Platform Could Lead to Mouse-Based Clinical TrialsIn this video, Dr. Edison Liu describes a novel patient-derived xenograft platform that might enable development of a mouse-based clinical trials program.
Latest:
ctDNA Increase May Predict Regorafenib Response in Advanced CRCIn this video, Pashalina Kehagias discusses how an early increase in ctDNA may predict a poor response to regorafenib in advanced CRC.
Latest:
Small-Molecule TKIs: Potential Benefit in Multiple MalignanciesIn this video, Dr. Brian Schwartz highlights several small-molecule TKIs in development with the potential to help patients with several malignancies.
Latest:
Breast Cancer and African AncestryIn this video, Dr. Melissa Davis explains how African ancestry may play a role in breast cancer, and ways that genetics might be used to help guide treatment.
Latest:
POINT: Chemotherapy vs Abiraterone for the Initial Management of Metastatic Prostate CancerChemotherapy is the best option for the initial management of metastatic prostate cancer.
